2018
DOI: 10.1002/rmb2.12102
|View full text |Cite
|
Sign up to set email alerts
|

Association of follicular fluid volume with membrane stretchability of human metaphase II oocytes following the gonadotropin‐releasing hormone agonist protocol during intracytoplasmic sperm injection

Abstract: PurposeThe authors previously revealed the association of the follicular fluid (FF) volume with oolemma stretchability following the gonadotropin‐releasing hormone (GnRH) antagonist protocol during intracytoplasmic sperm injection (ICSI). However, the impact of the GnRH agonist protocol on oolemma stretchability remains unclear.MethodsData that were obtained from 74 ICSI cycles were reviewed retrospectively. Controlled ovarian stimulation was performed in accordance with the short GnRH agonist protocol. Each f… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 30 publications
0
1
0
Order By: Relevance
“…Controlled ovarian stimulation was performed using a long, short, or gonadotropin‐releasing hormone (GnRH) antagonist protocol depending on the patient as described previously. 16 , 17 , 18 A GnRH analogue acetate (Fuji Pharma Co., Tokyo, Japan), human menopausal gonadotropin (ASKA Pharmaceutical Co., Tokyo, Japan), and a GnRH antagonist (Cetrotide; Merck KGaA, Darmstadt, Germany) were administered as dictated in these established protocols. When at least 2 follicles reached 18–20 mm in diameter (as determined by transvaginal ultrasonography), 5000 IU of hCG (Fuji Pharma Co.) was administered.…”
Section: Methodsmentioning
confidence: 99%
“…Controlled ovarian stimulation was performed using a long, short, or gonadotropin‐releasing hormone (GnRH) antagonist protocol depending on the patient as described previously. 16 , 17 , 18 A GnRH analogue acetate (Fuji Pharma Co., Tokyo, Japan), human menopausal gonadotropin (ASKA Pharmaceutical Co., Tokyo, Japan), and a GnRH antagonist (Cetrotide; Merck KGaA, Darmstadt, Germany) were administered as dictated in these established protocols. When at least 2 follicles reached 18–20 mm in diameter (as determined by transvaginal ultrasonography), 5000 IU of hCG (Fuji Pharma Co.) was administered.…”
Section: Methodsmentioning
confidence: 99%